Beneficial effect of Burdock complex on asymptomatic Helicobacter pylori‐infected subjects: A randomized, double‐blind placebo‐controlled clinical trial

• Published in: Helicobacter (Cambridge, Mass.) Vol. 23; no. 3; pp. e12469 - n/a
• Main Authors: Yen, Chi‐Hua, Chiu, Hui‐Fang, Huang, Su‐Yu, Lu, Yan‐Ying, Han, Yi‐Chun, Shen, You‐Cheng, Venkatakrishnan, Kamesh, Wang, Chin‐Kun
• Format: Journal Article
• Language: English
• Published: England Wiley Subscription Services, Inc 01.06.2018
• Subjects: Adhesion; Adhesion tests; AGS cells; Angelica sinensis - chemistry; Anti-Inflammatory Agents - chemistry; Anti-Inflammatory Agents - pharmacology; Anti-Inflammatory Agents - therapeutic use; antioxidant capacity; Antioxidants; Arctium - chemistry; Burdock complex; Cell Adhesion - drug effects; Cell Line, Tumor; Cell Survival - drug effects; Clinical trials; Double-Blind Method; Double-blind studies; Drugs, Chinese Herbal - chemistry; Drugs, Chinese Herbal - pharmacology; Drugs, Chinese Herbal - therapeutic use; Epithelial cells; Epithelial Cells - cytology; Epithelial Cells - immunology; Gastric Mucosa - metabolism; Helicobacter Infections - drug therapy; Helicobacter Infections - microbiology; Helicobacter Infections - pathology; Helicobacter pylori; Helicobacter pylori - drug effects; Herbal medicine; Humans; Inflammation; Inflammation - drug therapy; Inflammation - immunology; Inflammatory response; Lithospermum - chemistry; Markers; Minimum inhibitory concentration; Pathogens; Phenolic compounds; Phenols; Sesamum - chemistry; Stomach - pathology; Traditional Chinese medicine; Treatment Outcome; Ulcer - drug therapy; Ulcer - microbiology; Ulcer - pathology; Urea; Urea - metabolism; AGS cells; Burdock complex; Helicobacter pylori; antioxidant capacity; inflammation
• ISSN: 1083-4389; 1523-5378; 1523-5378
• DOI: 10.1111/hel.12469

Background Burdock complex (BC) constitutes of burdock (Arctium lappa), angelica (Angelica sinensis), gromwell (Lithospermum erythrorhizon), and sesame (Sesamum indicum) oil, which are commonly used in traditional Chinese medicine (TCM) for treating various disorders. This study intended to examine the anti‐H. pylori activity of BC on AGS cell model as well as in asymptomatic H. pylori‐infected subjects. Materials and Methods AGS cell incubated with H. pylori and treated with BC to evaluate the minimum inhibition concentration (MIC), cell viability (MTT) anti‐adhesion activity, and inflammatory markers. In case of clinical trial, H. pylori‐positive subjects (urea breath test [UBT] >10%, n = 36) were enrolled and requested to intake BC (n = 19) or placebo (n = 17) for 8 weeks. Antioxidant capacity, total phenol, UBT, inflammatory markers were analyzed at the initial, 4th, 8th, and 10th weeks. Moreover, the endoscopic examination was carried out on baseline and 10th week. Results In vitro studies showed that BC treatment significantly inhibited (P < .05) the inflammatory markers and adhesion of H. pylori to AGS cell. However, H. pylori‐infected subject ingested with BC for 8 weeks significantly decreased (P < .05) the UBT value, inflammatory markers with improved antioxidant activity, and phenolic levels as compared to placebo. Also, consumption of BC considerably healed the ulcer wound. Conclusion Overall, the BC could attenuate H. pylori infection by inhibiting H. pylori adhesion and subsequent inflammatory response on the gastric epithelial cell (AGS) as well as clinically ameliorated UBT, antioxidant capacity, and alleviated inflammation to display its anti‐H. pylori activity.